Risultati della ricerca - Joseph M. Gozgit

  • Mostra 1 - 9 risultati su 9
Raffina i risultati
  1. 1
    Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer

    Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer di Valentina De Falco, Preziosa Buonocore, Magesh Muthu, Liborio Torregrossa, Fulvio Basolo, Marc Billaud, Joseph M. Gozgit, Francesca Carlomagno, Massimo Santoro

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2

    Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2 di Joseph M. Gozgit, Geraldine Bebernitz, Pankaj Patil, Minwei Ye, Julie Parmentier, Jiaquan Wu, Nancy Su, Tao Wang, Stephanos Ioannidis, Audrey M. Davies, Dennis Huszar, Michael Zinda

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

    Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models di Joseph M. Gozgit, Matthew J. Wong, Lauren Moran, Scott Wardwell, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Tim Clackson, Victor M. Rivera

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

    Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies di Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell, Jeffrey W. Tyner, Marc Loriaux, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Brian J. Druker, Tim Clackson, Victor M. Rivera

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

    Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study di Neil P. Shah, Moshe Talpaz, Michael W. Deininger, Michael J. Mauro, Ian W. Flinn, Dale L. Bixby, Stephanie Lustgarten, Joseph M. Gozgit, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Hagop M. Kantarjian, Jorge E. Cortés

    Pubblicazione 2013
    Testo Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  6. 6
    Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

    Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients di Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa B. Schrock, Tianjun Zhou, César Serrano, Grant Eilers, Mei‐Jun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

    FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies di Murry W. Wynes, Trista K. Hinz, Dexiang Gao, Michael L. Martini, Lindsay A. Marek, Kathryn E. Ware, Michael G. Edwards, Diana Böhm, Sven Perner, Barbara A. Helfrich, Rafał Dziadziuszko, Jacek Jassem, Szymon Wojtylak, Aleksandra Sejda, Joseph M. Gozgit, Paul A. Bunn, D. Ross Camidge, Aik Choon Tan, Fred R. Hirsch, Lynn E. Heasley

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors

    Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors di Julie W. Reeser, Dorrelyn M. Martin, Jharna Miya, Esko A. Kautto, E. Lyon, Eliot Y. Zhu, Michele R. Wing, Amy Smith, Matthew Reeder, Eric Samorodnitsky, Hannah Parks, Karan R. Naik, Joseph M. Gozgit, Nicholas B. Nowacki, Kurtis D. Davies, Marileila Varella‐Garcia, Lianbo Yu, Aharon G. Freud, Joshua F. Coleman, Dara L. Aisner, Sameek Roychowdhury

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

    The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors di Michael Hedvat, Dennis Huszar, Andreas Herrmann, Joseph M. Gozgit, Anne Schroeder, Adam Sheehy, Ralf Buettner, David A. Proia, Claudia Kowolik, Xin Hong, Brian Armstrong, Geraldine Bebernitz, Shaobu Weng, Lin Wang, Minwei Ye, Kristen McEachern, Huawei Chen, Deborah Morosini, Kirsten Bell, Marat Alimzhanov, Stephanos Ioannidis, Patricia McCoon, Zhu Cao, Hua Yu, Richard Jove, Michael Zinda

    Pubblicazione 2009
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: